By Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
Patients last year petitioned the FDA to consider the treatment, called NurOwn, in a public hearing. The agency said the company submitted"scientifically incomplete" and"grossly deficient" data.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsThe biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Les mer »
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
Les mer »
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Les mer »
San Diego biotech will pay $200K after allegations of misleading claimsBiora Therapeutics made misleading claims regarding the costs of genetic testing services
Les mer »
Average teen gets more than 230 notifications on their cell phone each day, study findsA new study is shining a light on the amount of time teenagers are spending on their cell phones and social media every day.
Les mer »